5-methyl-3-(2H-tetrazol-5-yl)-1,4,5,6-tetrahydrocyclopentapyrazole | 1050199-72-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 5-methyl-3-(2H-tetrazol-5-yl)-1,4,5,6-tetrahydrocyclopentapyrazole
• 英文别名: 5-methyl-3-(2H-tetrazol-5-yl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole
• CAS: 1050199-72-8
• 化学式: C₈H₁₀N₆
• 分子量: 190.208
• InChiKey: ZLOQOYIWTGOTQI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  83.1
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-benzyl-5-methyl-3-(2H-tetrazol-5-yl)-5,6-dihydro-4H-cyclopenta[c]pyrazole 在 甲酸 、 钯 作用下， 以 甲醇 为溶剂， 以0.053 g的产率得到5-methyl-3-(2H-tetrazol-5-yl)-1,4,5,6-tetrahydrocyclopentapyrazole
  参考文献：
  名称：

  3-(1H-Tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): A Partial Agonist of the Nicotinic Acid Receptor, G-Protein Coupled Receptor 109a, with Antilipolytic but No Vasodilatory Activity in Mice

  摘要：

  The discovery and profiling of 3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopeiitapyrazole (5a, MK-0354), a partial agonist of GPR 109a, is described. Compound 5a retained the plasma free fatty acid lowering effects in mice associated with GPR109a agonism, but did not induce vasodilation at the maximum feasible dose. Moreover, preadministration of 5a blocked the flushing effect induced by nicotinic acid but not that induced by PGD(2). This profile made 5a a suitable candidate for further study for the treatment of dyslipidemia.

  DOI：

  10.1021/jm800258p

文献信息

• Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
  申请人：Semple Graeme

  公开号：US20070072924A1

  公开（公告）日：2007-03-29

  The present invention relates to certain tetrazole derivatives of Formula (I), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers and the like.

  本发明涉及公式（I）的某些四唑衍生物及其药学上可接受的盐，这些化合物具有有用的药理学特性，例如作为RUP25受体激动剂。本发明还提供包含该类化合物的制药组合物，并提供使用该类化合物和组合物治疗代谢相关疾病的方法，包括血脂异常、动脉硬化、冠心病、胰岛素抵抗、2型糖尿病、X综合症等。此外，本发明还提供使用该类化合物与其他活性剂联合使用的方法，例如α-葡萄糖苷酶抑制剂、醛糖还原酶抑制剂、双胍类药物、HMG-CoA还原酶抑制剂、角鲨烷合成抑制剂、纤维酸类药物、低密度脂蛋白降解增强剂、血管紧张素转换酶（ACE）抑制剂、胰岛素分泌增强剂等。
• US8637555B2
  申请人：——

  公开号：US8637555B2

  公开（公告）日：2014-01-28